FGFR4 and prostate carcinoma: Analysis stratified by cancer type indicated that FGFR4 rs351855 [A] carriers have modestly increased risk of developing breast cancer (homozygous: OR=1.73, 95% CI=1.35-2.20; recessive: OR=1.46; 95%CI=1.17-1.83; dominant: OR=1.25, 95% CI=1.02-1.52; allele contrast: OR=1.26; 95% CI=1.14-1.41), and prostate cancer (heterozygous: OR=1.16, 95% CI=1.02-1.32; dominant: OR=1.20, 95% CI=1.06-1.35; allele contrast: OR=1.22, 95% CI=1.06-1.41).